Abstract: Atypical fi broxanthoma is an uncommon mesenchymal tumor that manifests clinically as a reddish papule or nodule in sun-exposed areas of the body. The clinical presentation is not specifi c and histology and immunohistochemistry are both necessary for a correct diagnosis. Surgery is the gold standard of therapy. Recurrence and metastasis should be excluded with a follow-up at 6 months, since this tumor should nowadays be considered a medium-grade neoplasm, rather than low-grade as previously believed. We report the case of two friends who came to our hospital during the same period, complaining of very similar lesions. After biopsy and immunohistochemical examination, a diagnosis of atypical fi broxanthoma in both cases was formulated.
INTRODUCTION
AFX, also termed pseudosarcoma, paradoxical fi brosarcoma or pseudosarcomatous reticulohistiocytoma, is an uncommon superfi cial fi brohistiocytic tumor. It occurs mainly on sunexposed skin of elderly individuals and shows a male predominance. The lesion usually presents as an asymptomatic, solitary, often dome-shaped nodule, which may be ulcerated. Histologically, AFX consists of an admixture of highly pleomorphic spindle, epithelioid and multinucleated giant cells in the dermis. 1 The growth pattern of AFX has a propensity of local invasion beyond the involved skin, thereby presenting the risk of local recurrence after surgical excision, which is the gold standard of treatment.
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CASE REPORT
A 78-year-old healthy man was referred to our clinic due to the presence of a juicy-red, dome-shaped nodule. The nodule, 1cm in diameter, appeared on the left antihelix appeared approximately one year before ( Figure 1 ). Physical examination revealed sundamaged skin and a surgical scar due to previous excision of a basal cell carcinoma.
One week later, a friend of his (a 75-year-old man) came to our department with a similar skin lesion. The nodule was oval-shaped, exophytic and bleeding ( Figure 2 ). It was located on the right helix and had a diameter of 1.5cm. According to the patient, the lesion appeared about 2 months beforehand and had been increasing in size.
In both patients, we performed surgical removal of the lesions, suspecting basal cell carcinomas. Histological examination showed similar fi ndings in both samples such as central erosion associated with pleomorphic spindle and epithelioid cell infi ltration in the context of a thickened vascularized stroma ( Figure 3 and 4) . The proliferating cells were CD68+ ( Figure 5 ), CD163+, FXIII+ and smooth muscle actin+, while melanocytic markers (S100, melan-A, HMB45) were negative and melanoma was therefore excluded. A fi nal diagnosis of atypical fi broxanthoma (AFX) was made in both cases, which was subsequently treated via surgical excision. The 6-month follow-up did not reveal any new lesions in our patients.
DISCUSSION
AFX is a rare, rapidly growing neoplasm of intermediate malignant potential. AFX is typically asymptomatic, unilesional and localized in sun-exposed areas (nose, ears and lips) of elderly patients with a higher incidence in the seventh and eighth decade of life 4 . The pathogenesis is commonly related to ultraviolet exposure. Several studies have assessed a link to p53 protein and demonstrated signature mutations in the p53 gene, occurring from UV radiation 5 . Moreover x-ray exposure also seems to induce AFX development. A study conducted on 140 AFX cases revealed that 4.2% of lesions had been developing on previous radiation sites 1 . Immunohistochemistry is fundamental to properly diagnose AFX. CD68 and smooth muscle actin are highly positive, while HMB45 and S100 protein are negative 4 . AFX tumors usually have a benign clinical course. Surgical excision is the therapy of choice. Wide excision with safety margins (1-2cm) is recommended as a fi rst choice treatment 5 . In the rare metastatic cases, treatment is patient individualized.
Recurrence and metastasis occur rarely in incompletely excised tumors or when the subcutis or deeper structures are involved and/or tumor necrosis or perineural-vascular invasion is present. Since recurrences usually appear within months to 3 years after primary excision, a clinical follow-up should be performed every 3-6 months over a 2-3-year period. Inspection and palpation of skin, lymph nodes and loco-regional skin, in addition to lymph node sonography, are crucial studies 
